Skip to content

Effect of a Dietary Supplement on Weight Loss and Psychological Wellbeing in Overweight Individuals

Randomized Clinical Trial to Evaluate the Efficacy of a Dietary Supplement on Weight Loss and Psychological Wellbeing in Overweight Individuals

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05758363
Enrollment
60
Registered
2023-03-07
Start date
2023-03-09
Completion date
2023-11-30
Last updated
2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Brief summary

The aim of this randomized, parallel, two-arm, placebo-controlled, double-blind, multicenter clinical trial is to evaluate the efficacy of a dietary supplement on weight loss and psychological well-being in overweight individuals.

Detailed description

The duration of the study will be 6 months during which the investigational product or placebo will be consumed according to the assignment. Subjects will be randomized to each of the study arms (consumption of the experimental product or control product).

Interventions

DIETARY_SUPPLEMENTConsumption of dietary supplement.

Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.

OTHERConsumption of control product

Consumption of 1 capsule per day of control product of identical appearance with breakfast.

Sponsors

Universidad Católica San Antonio de Murcia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults (age: 30 - 70 YO) * BMI over 25 kg/m2. * Subjects who are smokers or non-smokers, but in any case who do not modify their nicotinic habits during their participation in the study.

Exclusion criteria

* Subjects with eating disorders. * BMI less than 25 Kg/m2. * History of allergic hypersensitivity or poor tolerance to any component of the products under study. * Participation in another clinical trial in the three months prior to the study. * Unwillingness or inability to comply with clinical trial procedures. * Pregnant woman. * Participants with an active daily exercise activity. * Subjects whose condition makes them ineligible for the study at the investigator's discretion.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of weight lossFrom baseline to 6 months laterEvaluation of weight loss by assessment of anthropometric measurements - Waist/hip ratio - Waist/height ratio.

Secondary

MeasureTime frameDescription
Quality of life by SF-36From baseline to 6 months laterShort Form 36 Health Survey Questionnaire (SF-36). The SF-36 contains 36 items that measure eight dimensions or scales. The scores for each dimension will be calculated in both raw and transformed form as indicated in the manual, with higher scores indicating better health status for that particular dimension.
DepressionFrom baseline to 6 months laterBeck Depression Inventory test. The score ranges from 0 to 63, where the higher the score, the greater the signs of depression.
Quality of life by WHOQOL-BREFFrom baseline to 6 months laterWorld Health Organization Quality of Life Brief version test. The raw scores are transformed into a normalized scale ranging from 4 to 20 and from 0 to 100. Higher scores indicating better quality of life.
AnxietyFrom baseline to 6 months laterState-Trait Anxiety Inventory (STAI) Test. Scores can vary between 0 to a maximum of 60. Higher scores correlate positively with higher levels of anxiety.
Dietary intakeFrom baseline to 6 months laterRegistration and subsequent nutritional evaluation with 3-day food frequency questionnaire (FFQ).
StressFrom baseline to 6 months laterPerceived Stress Scale (PSS). Total scores range from 0 to 56 (higher scores indicate higher levels of stress).

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026